Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Robert J. Glynn"'
Autor:
Sara K. Tedeschi, Seoyoung C. Kim, Sebastien Haneuse, Houchen Lyu, Elisabetta Patorno, Kazuki Yoshida, Daniel H. Solomon, Robert J. Glynn, Sonia Hernandez-Diaz
Publikováno v:
Pharmacoepidemiology and Drug Safety. 28:934-941
Purpose In observational research, equipoise concerns whether groups being compared are similar enough for valid inference. Empirical equipoise was previously proposed as a tool to assess patient similarity based on propensity scores (PS). We extende
Publikováno v:
Pharmacoepidemiology and Drug Safety. 28:665-670
Purpose Implementing a cohort study in longitudinal healthcare databases requires looking back over some covariate assessment period (CAP) preceding cohort entry to measure confounders. We used simulations to compare fixed-duration versus all-availab
Autor:
Michele Jonsson Funk, Charles Poole, Mitchell M. Conover, Ross J. Simpson, Robert J. Glynn, Til Stürmer, Virginia Pate
Publikováno v:
Pharmacoepidemiology and Drug Safety. 27:771-780
PURPOSE Evaluate use of fixed and all-available look-backs to identify eligibility criteria and confounders among Medicare beneficiaries. METHODS We identified outpatient visits (2007-2012) with recently documented (≤180 days) cardiovascular risk a
Autor:
Michael A. Fischer, Shirley V. Wang, Jessica M. Franklin, Krista F. Huybrechts, Sebastian Schneeweiss, Joshua J. Gagne, Robert J. Glynn
Publikováno v:
Pharmacoepidemiology and Drug Safety. 27:383-390
Purpose To explore generalized boosted modeling (GBM) as a method for identifying subgroups with greater benefit or harm with dabigatran versus warfarin for treatment of atrial fibrillation. Methods We identified new initiators of warfarin or dabigat
Autor:
Sonia Hernandez-Diaz, Robert J. Glynn, Sara K. Tedeschi, Tzu-Chieh Lin, Yinjuan Lian, Gail A. Greendale, Kristine Ruppert, Sebastien Haneuse, Daniel H. Solomon, Kazuki Yoshida, Zhi Yu
Publikováno v:
Pharmacoepidemiology and Drug Safety. 27:182-190
Purpose To examine the effects of analgesics on bone mineral density (BMD), which have not been examined in a longitudinal study with multiple measurements. Methods We investigated changes in BMD associated with new use of analgesics in a prospective
Autor:
Alexander M. Walker, Sebastian Schneeweiss, Anton Pottegård, Robert J. Glynn, Shirley V. Wang, Kenneth J. Rothman, Joshua J. Gagne, Martin Kulldorff
Publikováno v:
Wang, S V, Kulldorff, M, Glynn, R J, Gagne, J J, Pottegård, A, Rothman, K J, Schneeweiss, S & Walker, A M 2018, ' Reuse of data sources to evaluate drug safety signals : When is it appropriate? ', Pharmacoepidemiology and Drug Safety, vol. 27, no. 6, pp. 567-569 . https://doi.org/10.1002/pds.4442
Publikováno v:
Pharmacoepidemiology and Drug Safety. 25:755-762
Background Current methods for prospective drug safety monitoring focus on determining whether and when to generate safety alerts indicating that a new drug may be less safe than a comparator. Approaches are needed to develop safety thresholds that c
Autor:
Andrea V. Margulis, Robert J. Glynn, Sonia Hernandez-Diaz, Lewis B. Holmes, Murray A. Mittleman
Publikováno v:
Pharmacoepidemiology and Drug Safety. 24:343-352
Purpose This study aims to explore the influence of gestational age at enrollment, and enrollment before or after prenatal screening, on the estimation of drug effects in pregnancy exposure registries. Methods We assessed the associations between fir
Autor:
Christina D. Mack, M. Alan Brookhart, Anne Marie Meyer, William R. Carpenter, Robert S. Sandler, Robert J. Glynn, Til Stürmer
Publikováno v:
Pharmacoepidemiology and Drug Safety. 22:810-818
Purpose Nonexperimental studies of treatment effectiveness provide an important complement to randomized trials by including heterogeneous populations. Propensity scores (PSs) are common in these studies but may not adequately capture changes in chan
Autor:
Sonia Hernandez-Diaz, Colin R. Dormuth, Murray A. Mittleman, Andrea V. Margulis, Soko Setoguchi, Robert J. Glynn
Publikováno v:
Pharmacoepidemiology and Drug Safety. 22:16-24
Purpose The role of administrative databases for research on drug safety during pregnancy can be limited by their inaccurate assessment of the timing of exposure, as the gestational age at birth is typically unavailable. Therefore, we sought to devel